Journal
LANCET ONCOLOGY
Volume 16, Issue 7, Pages E333-E341Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(15)00080-7
Keywords
-
Categories
Funding
- National Palliative Care Research Center, Celgene
- Helsinn Therapeutics
- Agency for Healthcare Research and Quality
- National Institutes of Health
- Michigan Oncology Quality Consortium
- American Academy of Hospice and Palliative Medicine
- Advoset
- Orange Leaf Associates
- Athena Health
- Flatiron Health
- Pfizer
- ACORN Research
- Alliance for Clinical Trials in Oncology
- American Cancer Society
- Bristol-Myers Squibb
- Celgene
- DARA
- Denderon
- GlaxoSmithKline
- Helsinn Healthcare
- Kanglaite
- Mayo Clinic
- Medical College of Wisconsin
- Memorial Sloan Kettering Cancer Center
- University of North Carolina at Chapel Hill
- University of South Florida
- National Cancer Institute
- National Institute for Nursing Research
- National Institutes on Aging
Ask authors/readers for more resources
Polypharmacy is a well known problem in elderly patients in general, but its prevalence and effects in patients with cancer are less clear, particularly in end-of-life settings. This Review examines the existing literature on polypharmacy in advanced cancer and end-of-life settings by reviewing evidence-based approaches to reduce polypharmacy, and outlining the potential benefits of decreasing the number of drugs that patients with cancer can take, with emphasis on the need for thoughtful discontinuation initiatives in the context of life-limiting malignant disease. In view of the apparent burden of polypharmacy in patients with advanced cancer, we expect that greater attention to polypharmacy could lead to improvements in adverse drug events, cost, and possibly quality of life. However, few data for specific interventions in the advanced cancer population are available, and thus more research is warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available